

1 **Investigating the contribution of circulating inflammatory cytokines on**
2 **the link between obesity and COVID-19**

3 Zahra J. Khamis¹, Emmanouil Karteris¹, Amani Alhajeri², Steven G. Smith¹, Alexandra
4 Blakemore^{1,3,4}, Fotios Drenos^{1*}

5 **1 Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel**
6 **University London, London, UK**

7 **2 Government Hospitals, The Genetics Center, Manama, Kingdom of Bahrain**

8 **3 Department of Metabolism, Digestion and Reproduction, Imperial College London,**
9 **London, UK**

10 **4 College of Medicine, Nursing, and Health Science, University of Galway, Galway, Republic**
11 **of Ireland**

12 *** Correspondence: Dr Fotios Drenos**

13 **Department of Life Sciences, College of Health and Life Sciences, Brunel University**
14 **London, Kingston Lane, Uxbridge, Middlesex, UB8 3PH, United Kingdom. +44 (0)1895**
15 **266951- fotios.Drenos@brunel.ac.uk**

16 **Abstract**

17 **Background:** Coronavirus disease 2019 (COVID-19), is more severe in individuals with obesity.
18 Furthermore, a cytokine storm was observed in many critically ill patients with COVID-19. Since
19 adipose tissue secretes cytokines, we investigated whether cytokines mediate the effect of obesity
20 on COVID-19 severity.

21 **Methods:** Using two-sample Mendelian randomization analyses we assessed the causal effect of
22 body mass index (BMI) on COVID-19 severity. We then evaluated the BMI effect on 41
23 inflammatory cytokines, as well as on JAK-2, lymphocyte percentage and leptin. We also tested
24 the relationship between these immunological factors and COVID-19 severity. The estimates
25 obtained were used in a mediation analysis to understand the immunological factors linking BMI
26 to COVID-19 severity.

27 **Results:** Higher BMI increased the risk of COVID-19 severity. BMI was also causally associated
28 with 5 of the 41 inflammatory cytokines, HGF, TRAIL, IL 13, IL6, and IL 7. We identified TNF-
29 α and IL-8 as the only two inflammatory cytokines associated with COVID-19 severity. Leptin-
30 related genetic variation was associated with COVID-19 severity, but JAK-2 and lymphocyte
31 percentage were not. We found no statistical evidence of mediation of immunological factors tested
32 on the relationship between BMI and COVID-19 severity, although our estimate was 52.8%.

33 **Conclusions:** We replicated the previously reported association between BMI and COVID-19
34 severity. We identified the inflammatory cytokines elevated due to higher BMI. Other
35 inflammatory cytokines showed evidence for increasing COVID-19 severity. However, we were
36 unable to find statistical evidence of baseline levels of circulating cytokines, or additional factors
37 involved in a cytokine storm i.e. JAK-2, lymphocyte percentage, and leptin, mediating the link

38 between BMI and severe COVID-19. Although targeting specific cytokines will be of benefit in
39 the general population, further work on cytokine levels during early phases of COVID-19 infection
40 is needed to provide new approaches to decrease the risk of severe COVID-19 with higher BMI.

41

42 **Keywords:** COVID-19; SARS-CoV2; inflammatory cytokines; mediation analysis, Two-sample
43 Mendelian randomization (2SMR), Multivariable Mendelian randomization (MVMR), Janus
44 kinase 2 (JAK2), leptin, lymphocytes percentage.

45 **1 Background**

46 Obesity, the excessive accumulation of fat, is considered to be one of the major risk factors for
47 developing severe COVID-19 (1). Several studies indicate that, as body mass index (BMI)
48 increases, so does the risk of mechanical ventilation and ICU admission (2)

49 Adipose tissue (AT), where body fat is stored, is an active immune organ that regulates hormonal,
50 metabolic, and immune processes. AT plays an important role in the development of systemic and
51 local low-grade inflammation that is recognized by local infiltration of immune cells, and by
52 elevated circulating proinflammatory factors (3).

53 According to our current understanding, following infection with SARS-CoV2, resident
54 macrophages are activated in adipose tissue. M1-polarized macrophage recruitment promotes the
55 production of local and systematic pro-inflammatory cytokines (IL 8, IL 6, TNF α) resulting in a
56 type-1 immune response (Th1) (4). Individuals with obesity develop a chronic immune response
57 in adipose tissue, resulting in the production of B cells, T cells, and natural killer (NK) cells that
58 can produce a cytokine storm. A cytokine storm is the result of the activity of several immune cells
59 including dendritic cells, macrophages, natural killer cells and T and B lymphocytes. Upon viral
60 infection, the innate immune cells recognize the molecular structure of the invading virus, called
61 pathogen associated molecular patterns (PAMPs), by pattern recognition receptors (PRRs) around
62 the cells. The interaction between PRRs and PAMPs triggers signaling pathways that induce the
63 expression of genes encoding proinflammatory cytokines (5). The sudden increase in cytokines,
64 "the cytokine storm", results in accumulation of immune cells into the infection site, causing tissue
65 damage. This can include damage to endothelial cells, the vascular barrier, and its capillaries, as
66 well as diffuse alveolar damage, which may lead to multiorgan failure, and death (6).

67 The immune response cascade is also affected by other key players such as: leptin; Janus kinase 2
68 (JAK2); and lymphocytes (7). As well as regulating appetite and reproductive functions, leptin is
69 a proinflammatory adipokine secreted by adipose tissue. Thus, leptin contributes to inflammation
70 and may lead to chronic inflammation (7). It directly stimulates macrophages (M1 phenotype),
71 natural killer (NK) cells, dendritic cells (DC) and T-helper cells to secrete proinflammatory
72 cytokines such as IL1, IL6, and TNF α (8).

73 The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is the
74 most important signaling pathway of the leptin receptor. Upon leptin binding, JAK2 activation
75 occurs, which leads to STAT3 binding to phosphorylated tyrosine in leptin receptor followed by
76 expression of responsive genes (9). JAK2 might be imbalanced in patients with obesity could lead
77 to an exaggerated immune response (9).

78 Lymphocytes, mainly CD4+ T cells and CD8+ T-cells ; play an essential role as antiviral immunity
79 (10). Patients who had recovered from COVID-19 had high to normal levels of T-cells (11). In
80 severe cases of SARS-CoV2, patients have low levels of lymphocytes, mainly CD8+ (10).
81 Therefore, lymphocyte counts have been suggested as possible biomarkers to evaluate the severity
82 of COVID-19 in patients (11).

83 The link between obesity and COVID-19 severity has been hypothesized as being, at least partly,
84 due to the immune responses of visceral fat in patients with obesity (6). There have been several
85 reports describing the effects of inflammatory cytokines on COVID-19 infection (12) and the role
86 of obesity in increasing the severity of COVID-19 (10,11).

87 To test the mediating role of cytokines and related immunological markers in the relationship
88 between BMI and COVID-19 severity, we need to first understand the causal relevance and
89 direction of effects between the different factors. Mendelian randomization (MR) allows us to use

90 genetic variants associated with an exposure of interest as instrumental variables to assess
91 causality. When used as a two-sample approach, summary results from large genome-wide
92 association studies (GWAS) can be used, significantly increasing the number of people we can
93 include in the analysis and, thus, improving our statistical power to detect a modest effect on an
94 outcome (13).

95 In this study, using publicly-available data from exceptionally large GWAS including hundreds of
96 thousands of individuals and the Mendelian randomization methodology, we aim to investigate the
97 potential mediation role of 41 cytokines, leptin, JAK2, and lymphocyte percentage in the link
98 between obesity and COVID-19 severity. Identifying the mediators of the effect of obesity on
99 COVID-19 severity will allow us to provide epidemiological evidence for targeting specific
100 cytokines that might decrease the risk of COVID-19 on patients with obesity, and which might
101 also have wider consequences for other categories of patients.

102 **2 Materials and Methods**

103 *2.1. Study Design*

104 The study was performed through three MR analyses as outlined in Figure (1): (1) MR analysis
105 was used to estimate the causal association between BMI and severe COVID-19. (2) We also used
106 MR analysis to test the effect of BMI on circulating cytokines and related traits. (3) We conducted
107 MR analysis to identify the circulating cytokines and related traits causally relevant to COVID-19
108 severity. Finally, we tested whether any of the factors identified as associated with BMI and
109 COVID-19 severity shows evidence of a mediating role between the two, using a multivariable
110 MR and estimating the possible mediating effect.

111 *2.2. Selection of genetic instrument variables for BMI*

112 The genetic instruments for BMI were extracted from the Metabochip meta-analysis and
113 genome-wide association study conducted by Locke, *et al.* The study identified 289 BMI-
114 associated loci (at a p-value threshold of $< 5 \times 10^{-8}$) from 322,154 participants of European
115 descent (14).

116 2.3. *GWAS summary statistics for COVID-19 severity*

117 COVID-19 severity genetic association data were obtained from the COVID-19 host genetics
118 initiative (COVID-19 HG) GWAS meta-analysis (15) (<https://www.COVID-19hg.org/>). The
119 COVID-19 HG team has made summary data publicly available on multiple COVID-19 outcomes
120 from several studies. The data acquired for this analysis is with an accession ID: “GCST011073”
121 at the GWAS Catalog of European populations. The study is from May 13, 2020, which is the last
122 time point available before the wide release of the COVID-19 vaccination. Severity of infection is
123 defined as hospitalized COVID-19 Vs. not hospitalized COVID-19 release 5 and includes 38,984
124 European ancestry cases and 1,644,784 European ancestry controls. The relevant data can be
125 downloaded from (<https://www.ebi.ac.uk/gwas/studies/GCST011073>) (15).

126 2.4. *GWAS summary statistics for inflammatory cytokines and C-reactive protein*

127 The summary statistics for inflammatory cytokines were acquired from the work of Kalaoja, *et al.*
128 (12). The authors analyzed a cytokine panel (41 cytokines) from the National FINRISK Study
129 (1997 and 2002 cohorts) and the Cardiovascular Risk in Young Finns Study (YFS) The full
130 GWAS summary results for all 41 inflammatory cytokines are available through the University of
131 Bristol (<https://data.bris.ac.uk/data/dataset/3g3i5smgghp0s2uvm1doflkx9x>) (16).

132 2.5. *GWAS summary statistics for leptin levels, lymphocytes percentage, and Tyrosine-protein* 133 *kinase JAK2 levels*

134 The summary statistics for lymphocyte percentage of leukocytes were obtained from the study by
135 Jung H, et. al. (17) based on data of 174,488 individuals from the UK biobank with European
136 ancestry (U.K.). Lymphocyte percentage was measured by dividing the number of lymphocytes in
137 blood by the total number of white blood cells.

138 Summary statistics data for leptin levels were acquired from the published study by Yaghootkar H.
139 *et al.* (18) accession ID: “GCST90007310” and downloaded from the GWAS Catalog
140 <https://www.ebi.ac.uk/gwas/studies/GCST90007310>. Yaghootkar analyzed circulating leptin
141 levels in 49,909 European ancestry individuals for association with exonic genetic variants (18).

142 GWAS of tyrosine-protein kinase (JAK2) levels was obtained from a genome-wide association
143 study of serum proteins published by Gudjonsson. et.al (19), accession ID: “GCST90086866” and
144 was downloaded from the GWAS Catalog <https://www.ebi.ac.uk/gwas/studies/GCST90086866>.
145 The authors performed a GWAS for 5,355 European Icelandic ancestry individuals with 2,091
146 serum proteins including JAK2 measured through the SOMAmer platform (19).

147

148 2.6. Statistical Analysis

149 All analyses were performed using R (20). The TwoSampleMR package (21) was used for MR
150 and the ggplot2 package (22) for plots, unless otherwise stated. The inverse variance weighted
151 (IVW) approach was considered as the main MR analysis for estimating the causal relationships
152 unless there was evidence for directional pleiotropy. Directional pleiotropy was tested through the
153 intercept term of the MR Egger analysis method (23). In the presence of pleiotropy, we used the
154 weighted median estimate. All p-values with $P < 0.05$ were considered statistically significant. All
155 association estimates were reported as either odd ratios (OR) with 95% confidence intervals (CIs)

156 for binary outcomes, or as beta coefficients and 95% CIs for continuous outcome variables. The
157 mediation analysis was performed as described in the supplementary material of Burgess et al (24).
158 Causal Mediation analysis is a method that assesses a hypothetical causal effect of exposure and
159 outcome via a mediator. It separates the total effect into direct and indirect effect whereby the
160 indirect effect includes the hypothetical mediator to the outcome. The total effect is obtained from
161 the two main sample MR results. The direct effect of BMI on COVID-19 severity was estimated
162 using a Multivariable Mendelian randomization using the MVMR package in R. Multivariable MR
163 analysis allows the simultaneous estimation of causal effects of multiple exposures on an outcome
164 (25). The indirect effect can then be estimated as the difference between the total and direct effects
165 (*Figure 4*).

166 **3 Results**

167 3.1 The causal effect of BMI on COVID-19 severity

168 From the previously reported 289 BMI associated SNPs, 187 remained after removing variants
169 with linkage disequilibrium of $r^2 > 0.001$ with any other SNP. All 187 were found in the COVID-
170 19 severity data and were successfully harmonized between the two sets of results. The inverse
171 variance weighted (IVW) estimates showed that BMI was positively associated with COVID-19
172 hospitalization (OR=1.242; 95% CI 1.034 -1.317 , $p=1.63 \times 10^{-8}$). MR Egger was used to test the
173 existence of pleiotropy, and no evidence of directional pleiotropy was present (Intercept 0.0005, p -
174 value = 0.638).

175

176 3.2 The effect of BMI on inflammatory cytokines

177 We estimated the effect of BMI on 41 inflammatory cytokines. Genetically-predicted BMI was
178 positively associated with five inflammatory cytokines with P-value less than 0.05 as shown in

179 Supplementary Table 1 and Figure 2. The cytokine with the highest magnitude of effect from BMI
180 was hepatocyte growth factor (HGF) ($\beta = 0.277$, $se = 0.0703$, $p=8.00 \times 10^{-5}$). Other cytokines
181 affected included TNF-related apoptosis-inducing ligand (TRAIL) ($\beta = 0.221$, $se = 0.0678$, $p=1.09$
182 $\times 10^{-3}$), IL 13 ($\beta = 0.226$, $se = 0.0916$, $p=1.38 \times 10^{-2}$), IL 6 ($\beta = 0.148$, $se = 0.0638$, $p=2.01 \times 10^{-2}$)
183 and IL 7 ($\beta = 0.196$, $se = 0.0992$, $p=4.83 \times 10^{-2}$). None of the cytokines tested showed evidence of
184 decreasing with increasing BMI as shown in Figure 2 and Supplementary Table 1, though CTACK
185 was close ($b = -0.184$, $se = 0.097$, $p = 5.6 \times 10^{-2}$).

186

187 3.3 The effect of inflammatory cytokines on COVID-19 severity

188 We tested all 41 inflammatory cytokines for a causal association with COVID-19 severity. Of
189 these, two cytokines were positively associated with severity of COVID-19: TNF α (OR= 1.030
190 (95% CI 1.011-1.048, $p=1.72 \times 10^{-3}$) and IL 8 (OR=1.017; 95% CI 1.000 - 1.034, $p=4.88 \times 10^{-2}$).
191 On the other hand, HGF (OR=0.892; 95% CI 0.800-0.984, $p=1.46 \times 10^{-2}$) was the only cytokine
192 with evidence of being inversely associated with COVID-19 severity as shown in Figure 3 and
193 Supplementary Table 2. We found no evidence of directional pleiotropy for any of the associations
194 tested using the intercept of the MR Egger model (Figure 3 and Supplementary Table 2).

195 3.4 The effect of BMI on each of leptin, JAK2, and lymphocyte percentage

196 We analyzed the effect of BMI variants individually on leptin, JAK2, and lymphocyte percentage.
197 Genetically-predicted BMI was only statistically significantly associated with leptin ($\beta = 0.732$, se
198 $= 0.0798$, $p=4.756 \times 10^{-20}$). JAK2 ($\beta = 0.142$, $se = 0.101$, $p=0.16$) and lymphocytes ($\beta = 0.0475$,
199 $se = 0.0308$, $p=0.12$) showed no evidence of associations.

200 3.5 The effect of leptin, JAK2, and lymphocyte percentage on COVID-19 severity

201 Leptin-associated genetic variants were positively associated with COVID-19 severity
202 (OR=1.289; 95% CI: 1.0766-1.501, $p=1.92 \times 10^{-2}$), whilst no statistically significant evidence was
203 found between SNPs for JAK2 (OR= 1.006 (95% CI 0.950 – 1.061 , $p=0.83$) and lymphocyte
204 percentage (OR= 0.989 (95% CI 0.908-1.069, $p=0.78$) with COVID-19 severity.

205 3.6 Mediation Analysis

206 Since no single cytokine measure was associated with both BMI and COVID-19 severity. We
207 measured the indirect causal effect of BMI on COVID-19 severity via all inflammatory cytokines
208 together. Leptin was associated with both BMI and COVID-19 severity, and we also tested its
209 mediation effect (*Figure 4*).

210

211 3.6.1 MVMR of BMI and all inflammatory cytokines on COVID-19 severity

212 To examine the possible mediation effect of all inflammatory cytokines together, and due to the
213 strong correlation between cytokines, we followed a stepwise approach in building our MVMR
214 model by adding inflammatory cytokines, guided by the knowledge of immune response pathways
215 to identify those contributing independent information and exclude those causing collinearity. Four
216 non-correlated cytokines were included in the final model, BNGF, GROA, IL2RA, and
217 MIP1A(*Supplementary Table 3*). The direct effect of BMI (103 SNPs) on COVID-19 severity was
218 no longer statistically significant (OR= 0.969 (95% CI 0.812 – 1.125) (*Supplementary Table 3*, but
219 none of the inflammatory cytokines was statistically significant with COVID-19 severity
220 (*Supplementary Table 3*).

221 3.6.2 MVMR of BMI and leptin levels on COVID-19 severity.

222 When leptin was included as a conditional factor in the BMI to COVID-19 severity MR model
223 through MVMR, the direct effect of BMI (26 SNPs) on COVID-19 severity was no longer
224 statistically significant (OR= 0.9839 (95% CI 0.752 – 1.216).

225

226 3.7 Causal Mediation Analysis

227 The mediation of the joint inflammatory cytokines was tested. The BMI effect mediated by the
228 cytokines included in the model was estimated as 0.102 (CI -0.0542, 0.2585), but the confidence
229 intervals include 0, indicating lack of statistical significance for the estimate (*Supplementary*
230 *Table 4*). This represents 52.8% of the total BMI effect estimated, but despite its large value we
231 were not able to find statistical evidence of a mediation effect. Mediation analysis was performed
232 for leptin as it showed evidence of positive association with both BMI and COVID-19. We re-
233 estimated the total effect using the BMI SNPs from the MVMR and leptin causal mediation
234 analysis also showed no evidence of a significant association, indirect effect of 0.129 (CI -
235 0.1592, 0.4172). Again, although this was 19.7% of the BMI effect on COVID-19 severity, we
236 lack the statistical evidence to confirm its presence (*Supplementary Table 3*) .

237

238 4 Discussion

239 Several studies have identified obesity, particularly as measured by high body mass index (BMI),
240 as a risk factor for COVID-19 severity. Since obesity also promotes inflammation, the contribution
241 of cytokines in increasing the risk of severe COVID-19 has been hypothesized, but is not yet well
242 understood.

243 Severe forms of COVID-19 are also associated with an overreaction of the immune system through
244 a cytokine storm. Here, using a two sample Mendelian randomization approach we confirmed the
245 causal link between obesity, as measured by high BMI, with COVID-19 severity in the form of
246 hospitalization following an infection. We also established the causal effects of genetically-
247 predicted BMI on cytokines and of cytokines to COVID-19 severity. We investigated the effect of
248 BMI on leptin, JAK2 and lymphocyte percentage and their effect on COVID-19 severity.
249 Mediation analysis was performed for the examined risk factors on the link between BMI and
250 COVID-19 severity and although a large proportion of the link between the two can potentially be
251 explained by a combination of cytokines and leptin, we were not able to find clear statistical
252 evidence to support their mediating role.

253 Our results agree with both observational and MR studies done previously between BMI and
254 COVID-19 severity: persons with obesity are at higher risk of severe course of COVID infection.
255 The effect we estimated (OR = 1.207; 95% CI: 1.115–1.307;) is close to that reported by several
256 Mendelian randomization studies of BMI and COVID-19 severity. COVID-19 severity in high
257 BMI patients was also observed in a previously published meta-analysis of 167 studies including
258 3 million COVID-19 patients. The meta-analysis was performed to compare the association
259 between high BMI hospitalized patients and normal BMI COVID-19 hospitalized patients and the
260 outcome results showed that severity of COVID-19 is 1.5 times higher in obese patients compared
261 to non-obese patients. The slight overestimation of the effect of BMI indicates the possible
262 presence of confounding factors between the two. Further support for the causal relationship of
263 obesity to COVID-19 severity was seen in studies showing a decrease in COVID-19 severity in
264 patients following bariatric surgery (26).

265 We assessed 41 inflammatory cytokines to investigate possible mediators that may drive a more
266 severe reaction to the SARs-COV-2 in individuals with obesity. We found five inflammatory
267 cytokines affected by elevated BMI levels (HGF ,TRAIL, IL 13, IL 6, and IL 7). Supporting our
268 finding, the link between obesity and changes in the cytokine profile has also been previously
269 reported (27). Further, Dam et. al. reviewed an increase of proinflammatory cytokines; IL 1, IL 6,
270 and TNF α by inducing immune cell infiltration from adipose tissue in cell culture settings using
271 human primary adipocytes and found adipose cells are capable of promoting an inflammatory state
272 (28). A two sample Mendelian randomization performed by Kalaoja et. al. identified HGF, MCP-
273 1, and TRAIL as significantly associated with BMI variation (12).The increase of the affected
274 cytokines seen in our study is probably due to larger number of independently significant BMI
275 variants used compared to other studies.

276 We carried out two sample Mendelian randomization of inflammatory cytokines with COVID-19
277 severity and our results indicated causal associations with TNF α and IL 8. Both inflammatory
278 cytokines were investigated in several studies reporting the production of high levels of several
279 inflammatory cytokines as part of initiation of cytokine storm in COVID-19 infection such as IL
280 2, IL 6, IL 7, IL 8, IL 10, GSCF, IP10, MCP 1, MIP1 A, and TNF α (29–31).

281 We also carried out mediation analysis to investigate the role of inflammatory cytokines on the
282 link between BMI and COVID-19 severity. We found no statistical evidence of mediation by
283 inflammatory cytokines despite the potentially very large estimated proportion of the mediated
284 effect. Although several studies suggested a role for inflammatory cytokines in promoting COVID-
285 19 severity (32), and explained the role of inflammatory cytokines in obesity (27,33,34), or even
286 explored the network effect of adipokines and cytokines in SARS-CoV-2 (35), to our knowledge,

287 there is no published evidence of a mediating role of inflammatory cytokines on the relationship
288 between BMI and COVID-19 severity.

289 Other researchers have investigated the role of leptin on obesity (36,37) and leptin in COVID-19
290 patients (38,39). Our study confirmed the statistically significant effect of high BMI levels on
291 leptin and added to the evidence linking it to worsening COVID-19. Despite its known pro-
292 inflammatory effects, we were again unable to find any statistical evidence of a mediating role of
293 leptin in the relationship between BMI and COVID-19 severity and to our knowledge no published
294 study has reported this effect.

295 We also tested JAK-2 and lymphocyte percentage, both as causal consequence of BMI and as
296 causes of COVID-19 severity. We found no evidence for either. Sun, *et.al.* studied the causal role
297 of different white blood cells including lymphocytes percentage and found no significant role of
298 lymphocytes in COVID-19 severity (40). To our knowledge, no MR study has examined the role
299 of JAK-2 with COVID-19 severity. However, JAK-2 was observed to mediate the signaling
300 pathway of inflammatory cytokines (i.e.: IL 6)(41) and anti-JAK-2 inhibitors are suggested for use
301 to mitigate SARs-CoV-2 infection (42,43).

302 MR, since it uses genetic variants that commonly explain only a small part of the variation of the
303 exposure of interest, frequently require very large sample sizes to identify the modest associations
304 present (44) which has likely affected our ability to obtain statistical evidence for mediation despite
305 the high proportion of the effect explained. As GWAS efforts increase in size and more genetic
306 variants are identified, we may be able to confirm this effect in the future. This will require GWAS
307 for cytokines with comparable size to the ones available for BMI and COVID-19, though the
308 difficulty and cost in obtaining these measures may make this challenging. Our work contains
309 additional limitations. A major issue for all MR studies is pleiotropy. To ensure the validity of our

310 results, we used the MR-Egger method to test for the presence of directional pleiotropy. The results
311 indicated that our findings are unaffected by it, but pleiotropy remains a concern in all MR studies,
312 more so when positive effects are reported. In two-sample MR approaches, it is important to use
313 information from comparable populations as systematic changes between them may influence the
314 results (45). Here, our analysis is necessarily restricted to people of European ancestry, due to
315 relevant GWAS data availability. It is unclear whether our conclusions hold for other ancestries,
316 as some studies reported differences in the genetic architecture of the traits considered in this work
317 among different ancestries, particularly in inflammatory cytokines secretion and function.
318 Studying healthy individuals in GWAS might also not reflect the cytokine storm initiated in viral
319 infection. GWAS, though powerful, has limitations for studying cytokine response to viruses as it
320 captures genetic tendency, a snapshot, rather than the dynamic response during an infection.
321 Finally, the participants of the population study were studied in general without specification to
322 sex. Studies showed that inflammatory cytokines and COVID-19 severity are affected by hormonal
323 status especially in females during menopause (46) and pregnancy (47).

324 In our study we used two-sample Mendelian randomization to study the mediating role of
325 inflammatory cytokines and related traits in the link between COVID-19 severity and BMI. We
326 investigated the implications of obesity for inflammatory cytokine levels and related traits, and
327 their effect on COVID-19 severity. We found no secure evidence of proinflammatory cytokines,
328 or related traits, mediating the relationship between BMI and increased risk of severe COVID-19
329 in European populations, despite estimating a potentially large mediating effect. Given the
330 increasing levels of obesity worldwide and the establishment of COVID-19 as an endemic
331 infection, the effectiveness of targeting cytokines to break the link between obesity and COVID-
332 19 severity, remains an open question. Well-powered randomized control trials will be required to

333 confirm any suitable cytokine related interventions to control the impact of obesity on COVID-19
334 as done previously with the WHO Solidarity study (48). Our results in this respect remain
335 inconclusive. Further work towards better understanding the genetics of the cytokine response,
336 especially during early stages of infections, and the genetic mechanisms of cytokine storm
337 initiation will help us identify potential targets for intervention not only for response to COVID-
338 19 but also for other similar infections and potentially future pandemic-inducing infections.

339 **Abbreviations**

340 BMI: Body mass index

341 2SMR: Two-sample Mendelian randomization

342 MVMR: Multivariable Mendelian randomization

343 JAK2: Janus Kinase 2

344 IVW: inverse variance weighted approach

345

346 **Declarations**

347 **Ethics approval and consent to participate**

348 The work described has used published summary level data and no ethics approval is required or
349 consent for publication.

350 **Consent for publication**

351 Not applicable.

352 **Availability of data and materials**

353 The data used is openly available.

354 **Competing interests**

355 The authors have no competing interests relevant to this work to declare

356 **Funding**

357 This work is not associated with any funding.

358 **Clinical trial number**

359 Not applicable

360 **Authors' contributions**

361 Z.K. performed the research, data acquisition, data interpretation/analysis, manuscript drafting,
362 writing, and editing along with designing figures and creating and organizing tables. F.D. Research
363 Concept and design and supervision, A.B. Conceptualization. F.D., A.B., E.K., A.A, and S.S.
364 review and editing. All authors have read and approved the final manuscript.

365 **Corresponding authors**

366 Correspondence to Fotios Drenos

367 **Acknowledgments**

368 Not applicable

369 **7 References**

- 370 1. de Leeuw AJM, Oude Luttikhuis MAM, Wellen AC, Müller C, Calkhoven CF. Obesity and its
371 impact on COVID-19. *J Mol Med Berl Ger.* 2021 Apr 6;
- 372 2. Zhang X, Lewis AM, Moley JR, Brestoff JR. A systematic review and meta-analysis of obesity and
373 COVID-19 outcomes. *Sci Rep.* 2021 Mar 30;11:7193.
- 374 3. Nguyen MTA, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, et al. A Subpopulation of
375 Macrophages Infiltrates Hypertrophic Adipose Tissue and Is Activated by Free Fatty Acids via
376 Toll-like Receptors 2 and 4 and JNK-dependent Pathways. *J Biol Chem.* 2007 Nov
377 30;282(48):35279–92.
- 378 4. Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, cytokines
379 and immunosuppression: what can we learn from severe acute respiratory syndrome? *Clin Exp*
380 *Rheumatol.* 2020;38(2):337–42.
- 381 5. Cao X. COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol.*
382 2020;20(5):269–70.
- 383 6. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What
384 We Know So Far. *Front Immunol.* 2020;11:1446.
- 385 7. Naylor C, Petri WA. Leptin Regulation of Immune Responses. *Trends Mol Med.* 2016
386 Feb;22(2):88–98.
- 387 8. Maurya R, Sebastian P, Namdeo M, Devender M, Gertler A. COVID-19 Severity in Obesity: Leptin
388 and Inflammatory Cytokine Interplay in the Link Between High Morbidity and Mortality. *Front*

- 389 Immunol [Internet]. 2021 Jun 18 [cited 2024 Mar 14];12. Available from:
390 <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.649359/full>
- 391 9. Tu R, Liu X, Dong X, Li R, Liao W, Hou J, et al. Janus kinase 2 (JAK2) methylation and obesity: A
392 Mendelian randomization study. *Nutr Metab Cardiovasc Dis*. 2021 Nov 29;31(12):3484–91.
- 393 10. Ilg Z, Muller G, Mueller M, Nippert J, Allen B. Analysis of absolute lymphocyte count in patients
394 with COVID-19. *Am J Emerg Med*. 2021 Aug 1;46:16–9.
- 395 11. Rezaei M, Marjani M, Tabarsi P, Moniri A, Pourabdollah M, Abtahian Z, et al. Evaluation of
396 Lymphocyte Subtypes in COVID-19 Patients. *Tanaffos*. 2022 Mar;21(3):293–301.
- 397 12. Kalaoja M, Corbin LJ, Tan VY, Ahola-Olli AV, Havulinna AS, Santalahti K, et al. The Role of
398 Inflammatory Cytokines as Intermediates in the Pathway from Increased Adiposity to Disease.
399 *Obesity*. 2021;29(2):428–37.
- 400 13. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian
401 randomization analyses using summarized data. *Int J Epidemiol*. 2017 Dec 1;46(6):1734–9.
- 402 14. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass
403 index yield new insights for obesity biology. *Nature*. 2015 Feb;518(7538):197–206.
- 404 15. The COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative
405 to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2
406 virus pandemic. *Eur J Hum Genet*. 2020 Jun;28(6):715–8.
- 407 16. Corbin LJ, Timpson NJ. Cytokines GWAS results. University of Bristol; 2020.

- 408 17. Jung H, Jung HU, Baek EJ, Kwon SY, Kang JO, Lim JE, et al. Integration of risk factor polygenic risk
409 score with disease polygenic risk score for disease prediction. *Commun Biol.* 2024 Feb
410 13;7(1):180.
- 411 18. Yaghootkar H, Zhang Y, Spracklen CN, Karaderi T, Huang LO, Bradfield J, et al. Genetic Studies
412 of Leptin Concentrations Implicate Leptin in the Regulation of Early Adiposity. *Diabetes.* 2020
413 Dec;69(12):2806–18.
- 414 19. Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer LJ, et al.
415 A genome-wide association study of serum proteins reveals shared loci with common
416 diseases. *Nat Commun.* 2022 Jan 25;13(1):480.
- 417 20. R Core Team. R: A language and environment for statistical computing. R Foundation for
418 Statistical Computing. 2024 [cited 2024 Jul 20]. R: The R Project for Statistical Computing.
419 Available from: <https://www.r-project.org/>
- 420 21. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform
421 supports systematic causal inference across the human phenome. Loos R, editor. *eLife.* 2018
422 May 30;7:e34408.
- 423 22. Wickham H. *ggplot2: Elegant Graphics for Data Analysis* [Internet]. Springer-Verlag New York;
424 2016. Available from: <https://ggplot2.tidyverse.org>
- 425 23. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect
426 estimation and bias detection through Egger regression. *Int J Epidemiol.* 2015;44(2):512–25.

- 427 24. Burgess S, Daniel RM, Butterworth AS, Thompson SG. Network Mendelian randomization: using
428 genetic variants as instrumental variables to investigate mediation in causal pathways. *Int J*
429 *Epidemiol.* 2015 Apr;44(2):484–95.
- 430 25. Burgess S, Thompson SG. Multivariable Mendelian Randomization: The Use of Pleiotropic
431 Genetic Variants to Estimate Causal Effects. *Am J Epidemiol.* 2015 Feb 15;181(4):251–60.
- 432 26. Hasnain N, Moeed A, Waqar E, Farhan SA, Amreek F. Efficacy of bariatric surgery in COVID-19
433 patients: An updated systematic review and meta-analysis. *Surg Pract Sci.* 2022
434 Dec;11:100140.
- 435 27. Fantuzzi G. Adipose tissue, adipokines, and inflammation. *J Allergy Clin Immunol.* 2005 May
436 1;115(5):911–9.
- 437 28. Dam V, Sikder T, Santosa S. From neutrophils to macrophages: differences in regional adipose
438 tissue depots. *Obes Rev.* 2016;17(1):1–17.
- 439 29. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An
440 inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med.* 2020
441 Oct;26(10):1636–43.
- 442 30. Frisoni P, Neri M, D’Errico S, Alfieri L, Bonuccelli D, Cingolani M, et al. Cytokine storm and
443 histopathological findings in 60 cases of COVID-19-related death: from viral load research to
444 immunohistochemical quantification of major players IL-1 β , IL-6, IL-15 and TNF- α . *Forensic Sci*
445 *Med Pathol.* 2022;18(1):4–19.
- 446 31. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019
447 novel coronavirus in Wuhan, China. *Lancet Lond Engl.* 2020;395(10223):497–506.

- 448 32. Hasanvand A. COVID-19 and the role of cytokines in this disease. *Inflammopharmacology*.
449 2022;30(3):789–98.
- 450 33. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations
451 of CRP, TNF- α and IL-6. *Diabetes Res Clin Pract*. 2005 Jul 1;69(1):29–35.
- 452 34. Zuydam NV, Wielscher M, McCarthy M, Jarvelin MR. Increased Obesity Is Causal for Increased
453 Inflammation—A Mendelian Randomisation Study. *Diabetes*. 2018 Jul
454 1;67(Supplement_1):217-LB.
- 455 35. Nigro E, D’Agnano V, Quarcio G, Mariniello DF, Bianco A, Daniele A, et al. Exploring the Network
456 between Adipocytokines and Inflammatory Response in SARS-CoV-2 Infection: A Scoping
457 Review. *Nutrients*. 2023 Aug 30;15(17):3806.
- 458 36. Kim JW, Kim JH, Lee YJ. The Role of Adipokines in Tumor Progression and Its Association with
459 Obesity. *Biomedicines*. 2024 Jan;12(1):97.
- 460 37. Nambi G, Alghadier M, Elnegamy TE, Basuodan RM, Alwhaibi RM, Vellaiyan A, et al. Clinical
461 (BMI and MRI) and Biochemical (Adiponectin, Leptin, TNF- α , and IL-6) Effects of High-Intensity
462 Aerobic Training with High-Protein Diet in Children with Obesity Following COVID-19 Infection.
463 *Int J Environ Res Public Health*. 2022 Jun 11;19(12):7194.
- 464 38. Boicean LC, Birlutiu RM, Birlutiu V. Correlations between serum leptin levels and classical
465 biomarkers in SARS-CoV-2 infection, in critically ill patients. *Microb Pathog*. 2023
466 Sep;182:106238.

- 467 39. Réus GZ, Recco KCC, Machado KMSH, Silva RH, Arent CO, Amboni G, et al. COVID-19, Anxiety,
468 and Body Mass Index Increase Leptin Levels: a Cross-sectional Multicentric Study. *Mol*
469 *Neurobiol.* 2023 Dec 20;
- 470 40. Sun Y, Zhou J, Ye K. White Blood Cells and Severe COVID-19: A Mendelian Randomization Study.
471 *J Pers Med.* 2021 Mar 12;11(3):195.
- 472 41. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for
473 monocytes and macrophages. *Nat Rev Immunol.* 2020 Jun;20(6):355–62.
- 474 42. Khaledi M, Sameni F, Yahyazade S, Radandish M, Owlia P, Bagheri N, et al. COVID-19 and the
475 potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. *Front Med*
476 [Internet]. 2022 Aug 30 [cited 2024 Jul 22];9. Available from:
477 <https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.961027/full>
- 478 43. Levy G, Guglielmelli P, Langmuir P, Constantinescu SN. JAK inhibitors and COVID-19. *J*
479 *Immunother Cancer.* 2022 Apr 22;10(4):e002838.
- 480 44. Burgess S. Sample size and power calculations in Mendelian randomization with a single
481 instrumental variable and a binary outcome. *Int J Epidemiol.* 2014 Jun;43(3):922–9.
- 482 45. Carress H, Lawson DJ, Elhaik E. Population genetic considerations for using biobanks as
483 international resources in the pandemic era and beyond. *BMC Genomics.* 2021 May
484 17;22(1):351.
- 485 46. Gersh F, Lavie CJ, O’Keefe JH. Menopause Status and Coronavirus Disease 2019 (COVID-19).
486 *Clin Infect Dis.* 2021 Nov 1;73(9):e2825–6.

- 487 47. Ntounis T, Prokopakis I, Koutras A, Fasoulakis Z, Pittokopitou S, Valsamaki A, et al. Pregnancy
488 and COVID-19. *J Clin Med*. 2022 Nov 9;11(22):6645.
- 489 48. Pan H, Peto R, Henao Restrepo AM, Preziosi MP, Sathiyamoorthy V, Karim QA, et al. Remdesivir
490 and three other drugs for hospitalised patients with COVID-19: final results of the WHO
491 Solidarity randomised trial and updated meta-analyses. *The Lancet*. 2022 May
492 21;399(10339):1941–53.
- 493




Figure 1 A simplified illustration of total effect, direct, and indirect effect using two sample Mendelian randomization. Direct effect between exposure (BMI variants) and outcome (COVID-19 severity) is C' . Indirect effect between exposure and outcome through mediator (cytokines) is $a'+b'$. The total effect is Direct effect + Indirect effect.




Figure 2 Causal effect (betas) from the Two Sample Mendelian randomization analysis of body mass index (BMI) (exposure) with inflammatory cytokines (outcome)




Figure 3 Causal effect estimates (odds ratios and 95% confidence intervals) from the Two-Sample Mendelian randomization analysis of inflammatory cytokines (exposure) with COVID-19 severity (outcome).




Figure 4: A simplified illustration of mediation analysis, direct, and indirect effect using two sample mendelian randomization. Direct effect between exposure (BMI variants) and outcome (COVID-19 severity) . Indirect effect between exposure and outcome through mediator (cytokines, JAK2, Leptin, and lymphocytes percentage).